Abstract
Early assessment of treatment response is crucial in patients with soft-tissue sarcoma. A prospective study has examined whether changes in tumor 18F-fluorodeoxyglucose (FDG) uptake could predict histopathologic treatment response in patients with high-grade softtissue sarcoma after the initial cycle of neoadjuvant chemotherapy. Neoadjuvant chemotherapy is often ineffective and is associated with adverse effects; early prediction of response is, therefore, necessary. As changes in tumor size cannot predict histopathologic response and patients’ outcomes early during the course of therapy, the combination of FDG-PET with CT might be an important strategy in the management of patients with sarcoma. In total, 50 patients with highgrade soft-tissue sarcoma undergoing neoadjuvant chemotherapy and tumor resection were prospectively enrolled in the study. Combined FDG-PET and CT ImagIng
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
